Product milestones and publications, with a clear distinction between company announcements and clinical evidence.
· COMPANY ANNOUNCEMENT
The company announced an AI-assisted decision-support component for integrating profiling information and organizing options for professional review. Its announcement describes a retrospective in-silico analysis, which should be distinguished from a prospective clinical outcome study.
· PEER-REVIEWED PUBLICATION
A pilot study examined treatment informed by a blood-based profiling approach in advanced refractory cancers. Read the cohort definitions, outcomes, and limitations together.
Read the study summary· PEER-REVIEWED PUBLICATION
A study reported outcomes for patients receiving profiling-informed combinations involving angiogenesis inhibitors. The summary identifies the design and limitations.
Read the study summary· PEER-REVIEWED PUBLICATION
The RESILIENT publication reports outcomes from a study of integrated tumor analysis in advanced refractory cancers.
Read the study summarySelected milestones from the materials available for this UAT review; this is not an exhaustive or real-time news feed. Announcements about other Datar services do not establish regulatory status or performance for Exacta.
Browse the original global announcements archive